EE05474B1 - Antikehade kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud v„hivastaseks vaktsineerimiseks - Google Patents

Antikehade kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud v„hivastaseks vaktsineerimiseks

Info

Publication number
EE05474B1
EE05474B1 EEP200100366A EEP200100366A EE05474B1 EE 05474 B1 EE05474 B1 EE 05474B1 EE P200100366 A EEP200100366 A EE P200100366A EE P200100366 A EEP200100366 A EE P200100366A EE 05474 B1 EE05474 B1 EE 05474B1
Authority
EE
Estonia
Prior art keywords
antibodies
preparation
pharmaceutical composition
vaccination
antiviral
Prior art date
Application number
EEP200100366A
Other languages
English (en)
Estonian (et)
Inventor
Eckert Helmut
Loibner Hans
Original Assignee
Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag filed Critical Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag
Publication of EE200100366A publication Critical patent/EE200100366A/xx
Publication of EE05474B1 publication Critical patent/EE05474B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200100366A 1999-01-13 2000-01-12 Antikehade kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud v„hivastaseks vaktsineerimiseks EE05474B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH5199 1999-01-13
PCT/EP2000/000174 WO2000041722A1 (fr) 1999-01-13 2000-01-12 Utilisation d'anticorps pour effectuer une vaccination contre le cancer

Publications (2)

Publication Number Publication Date
EE200100366A EE200100366A (et) 2002-10-15
EE05474B1 true EE05474B1 (et) 2011-10-17

Family

ID=4178206

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100366A EE05474B1 (et) 1999-01-13 2000-01-12 Antikehade kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud v„hivastaseks vaktsineerimiseks

Country Status (28)

Country Link
US (3) US7691372B2 (fr)
EP (2) EP1140168B1 (fr)
JP (1) JP4774551B2 (fr)
KR (1) KR100771752B1 (fr)
CN (1) CN1188169C (fr)
AT (2) ATE219687T1 (fr)
AU (1) AU768515B2 (fr)
CA (1) CA2360382C (fr)
CZ (1) CZ302801B6 (fr)
DE (2) DE50000243D1 (fr)
DK (2) DK1230932T3 (fr)
EE (1) EE05474B1 (fr)
ES (2) ES2236375T3 (fr)
HK (1) HK1044487B (fr)
HR (1) HRP20010526A2 (fr)
HU (1) HU226150B1 (fr)
ID (1) ID30223A (fr)
IL (2) IL144265A0 (fr)
IS (1) IS5998A (fr)
MX (1) MXPA01007148A (fr)
NO (1) NO329917B1 (fr)
NZ (1) NZ512722A (fr)
PL (1) PL201533B1 (fr)
PT (2) PT1230932E (fr)
SI (2) SI1230932T1 (fr)
SK (1) SK286627B6 (fr)
TR (1) TR200102034T2 (fr)
WO (1) WO2000041722A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226150B1 (en) * 1999-01-13 2008-05-28 Igeneon Krebs Immuntherapie Use of antibodies for anticancer vaccination
AT410172B (de) 2000-03-21 2003-02-25 Igeneon Gmbh Verfahren zur herstellung einer vakzineformulierung
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
AT500647A1 (de) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie Verwendung eines impfstoffes
AT500650B1 (de) 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
US7759464B2 (en) 2004-07-14 2010-07-20 Greenovation Biotech Gmbh N-glycosylated antibody
EP1618890B1 (fr) * 2004-07-20 2010-10-06 Altropus Gmbh Utilisation d'anticorps en très faibles doses pour vaccination contre le cancer
CN103285392A (zh) * 2005-04-26 2013-09-11 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和其用途
WO2007008943A2 (fr) 2005-07-08 2007-01-18 Xencor, Inc. Proteines optimisees qui ciblent la molecule ep-cam
EP1762575A1 (fr) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification d' antigènes associés aux tumeurs pour diagnose et thérapie
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
CN101969966B (zh) 2007-12-07 2013-05-08 努特里希亚公司 用于尘螨变态反应的双歧杆菌
AU2010217120B2 (en) 2009-02-24 2014-11-20 Novartis Ag Methods for identifying immunobinders of cell-surface antigens
US8887373B2 (en) 2012-02-24 2014-11-18 Covidien Lp Vessel sealing instrument with reduced thermal spread and method of manufacture therefor
US20140276968A1 (en) * 2013-03-14 2014-09-18 Ethicon, Inc. Applicator systems for surgical fasteners
US10196458B2 (en) * 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341281C (fr) * 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Traitement par immunotherapie d'une tumeur, faisant appel a des anticorps monoclonaux de l'antigene 17-1a
US5270202A (en) * 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
WO1997005597A1 (fr) * 1995-07-31 1997-02-13 Litton Systems Canada Limited Ensemble de pixels a ecran plat incorporant des commutateurs photoconducteurs
EP0857176A1 (fr) * 1995-10-25 1998-08-12 Centocor B.V. PEPTIDES DERIVES DE L'Ep-CAM ANTIGENE EPITHELIAL HUMAIN ET LEUR EMPLOI
US6235280B1 (en) * 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
IL121041A0 (en) * 1997-06-09 1997-11-20 Yeda Res & Dev Immunogenic compositions for induction of anti-tumor immunity
US6274143B1 (en) * 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
IL139700A (en) * 1998-06-15 2005-09-25 Altarex Medical Corp Immunotherapeutic composition for the treatment of prostate cancer
HU226150B1 (en) * 1999-01-13 2008-05-28 Igeneon Krebs Immuntherapie Use of antibodies for anticancer vaccination
WO2001087233A2 (fr) * 2000-05-16 2001-11-22 New York University Anticorps anti-idiotypes diriges contre l'adhesine fimh d'escherichia coli uropathogene fimbrie du type i, compositions le contenant et son procede d'utilisation

Also Published As

Publication number Publication date
KR20010101446A (ko) 2001-11-14
NO20013093D0 (no) 2001-06-21
SI1140168T1 (en) 2002-10-31
HK1044487B (zh) 2005-09-16
HK1044487A1 (en) 2002-10-25
US20100233178A1 (en) 2010-09-16
US20070224202A1 (en) 2007-09-27
DE50009240D1 (de) 2005-02-17
PL201533B1 (pl) 2009-04-30
CA2360382C (fr) 2011-05-24
HU226150B1 (en) 2008-05-28
JP2002534481A (ja) 2002-10-15
ID30223A (id) 2001-11-15
ATE219687T1 (de) 2002-07-15
PL364747A1 (en) 2004-12-13
NZ512722A (en) 2003-07-25
US8444974B2 (en) 2013-05-21
CZ20012581A3 (cs) 2002-01-16
EE200100366A (et) 2002-10-15
JP4774551B2 (ja) 2011-09-14
EP1230932A3 (fr) 2003-11-26
ES2236375T3 (es) 2005-07-16
CA2360382A1 (fr) 2000-07-20
AU768515B2 (en) 2003-12-18
CN1344167A (zh) 2002-04-10
SK286627B6 (sk) 2009-02-05
PT1140168E (pt) 2002-11-29
ATE286745T1 (de) 2005-01-15
CZ302801B6 (cs) 2011-11-16
US20120003232A1 (en) 2012-01-05
DK1230932T3 (da) 2005-04-25
SI1230932T1 (en) 2005-06-30
DK1140168T3 (da) 2002-09-30
IS5998A (is) 2001-07-10
CN1188169C (zh) 2005-02-09
WO2000041722A1 (fr) 2000-07-20
SK9642001A3 (en) 2002-03-05
EP1140168B1 (fr) 2002-06-26
PT1230932E (pt) 2005-04-29
HRP20010526A2 (en) 2002-08-31
US7691372B2 (en) 2010-04-06
KR100771752B1 (ko) 2007-10-30
TR200102034T2 (tr) 2001-11-21
EP1140168A1 (fr) 2001-10-10
MXPA01007148A (es) 2002-03-27
ES2177509T3 (es) 2002-12-16
HUP0200527A2 (en) 2002-06-29
IL144265A (en) 2006-08-20
IL144265A0 (en) 2002-05-23
EP1230932B1 (fr) 2005-01-12
EP1230932A2 (fr) 2002-08-14
DE50000243D1 (de) 2002-08-01
NO20013093L (no) 2001-09-10
NO329917B1 (no) 2011-01-24
AU2796400A (en) 2000-08-01

Similar Documents

Publication Publication Date Title
EE05474B1 (et) Antikehade kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud v„hivastaseks vaktsineerimiseks
TR200001253T2 (tr) Tümöre özel antijenler
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
DK1270595T3 (da) Anti-CCR4-antistof og dets fragment
EA201300022A1 (ru) Терапевтическое человеческое моноклональное антитело против il-1r1
BR0108471A (pt) Objeto pré-formado para liberar um agente ativo a um paciente, e, processos de formação de um objeto pré-formado para liberar um agente e de liberação de um agente ativo a um paciente
NZ527283A (en) Modified antibodies and methods of use
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
BR0014652A (pt) Fabricação de conjugados de agente terapêutico-poliglutamato
CY1106400T1 (el) Συνθεση και μεθοδος ανοσοθepαπειας με καρκινικο αντιγονο
MY162623A (en) Immunoglobulin formulation and method of preparation thereof
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
ATE407147T1 (de) Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein
BRPI0508813B8 (pt) vacinas líquidas de combinação com baixa dose de conjugado de hib
ATE274919T1 (de) Feste dispergierende impfstoffe-zusammensetzung zur oralen verabreichung
BR0010711A (pt) Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
EP1354896A4 (fr) Nouvel anticorps monoclonal
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos
KR900011477A (ko) 항-트립타아제 항체 및 이것을 사용한 후천성 면역결핍증 치료용 조성물
MY143402A (en) Preparations used in the treatment and prophilaxis of mycobacterial infections
BR0007814A (pt) Uso de anticorpos para a vacinação contra câncer
AU2003294192A8 (en) Inclusion bodies as antigens for the oral vaccination of animals
BR9815993A (pt) Comprimido de liberação cronometrada compreendendo naproxen e pseudoefedrina
ITRM940453A0 (it) "uso della proteina p1lsa per la preparazione di un medicamento da utilizzarsi nella terapia di patologie indotte da danni cellulari da agenti fisici, chimici o biologici"

Legal Events

Date Code Title Description
MM4A Lapsed by not paying the annual fees

Effective date: 20130112